Livmoniplimab Biosimilar - Research Grade

Human

TGFB1, LRRC32

>1mg/ml

Human IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P01137;Q14392

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of livmoniplimab, supplied strictly for research use only. It is built as a human IgG4-kappa molecule directed against the GARP:latent-TGFβ1 complex, reproducing the target specificity of the originator drug so that laboratories can study GARP-mediated latent-TGFβ1 presentation and activation in controlled settings. It is not the clinical product and is not intended for human or veterinary use. Typical research applications include use as a binding and neutralisation reagent, an isotype-matched positive control in complex-directed assays, a benchmarking tool alongside other anti-GARP/TGFβ reagents, and a starting point for ADCC or antibody-engineering workflows. The material is offered at research grade with low endotoxin (<1 EU/mg research grade; <0.5 EU/mg ultra-low option) and is available in bulk milligram-to-gram quantities to support in-vitro assay development, preclinical characterisation, and formulation studies. Because it is a defined recombinant human IgG4, it provides lot-consistent performance for reproducible comparative work. Guidance is provided for ichorbio to review before publication. GARP (glycoprotein A repetitions predominant), encoded by LRRC32, is a transmembrane leucine-rich-repeat protein that acts as a cell-surface docking receptor for latent TGFβ. It binds the latency-associated peptide (LAP) of pro-TGFβ1 (encoded by TGFB1) via disulfide bonds, tethering the latent complex to the membrane of regulatory T cells, activated platelets, and other cell types. This GARP:latent-TGFβ1 complex concentrates the cytokine at the cell surface and, together with integrins and mechanical force, promotes release of mature, active TGFβ1. Active TGFβ1 signals through TGFBR1/TGFBR2 and SMAD pathways to drive immunosuppression, Treg function, fibrosis, and tissue homeostasis. In tumours, GARP-dependent TGFβ1 activation contributes to an immunosuppressive microenvironment, making the surface-restricted GARP:latent-TGFβ1 complex an attractive, cell-context-specific target compared with systemic TGFβ neutralisation.

Garpin, Glycoprotein A repetitions predominant, GARP, Leucine-rich repeat-containing protein 32, Transforming growth factor beta-1 proprotein, Transforming growth factor beta activator LRRC32, TGFB1, TGFB, LRRC32, D11S833E

Detects human TGFB1, LRRC32

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks